Efficacy, safety and reversibility of bisdiamine as a male contraceptive in cats

Linda Munson, Lisa M. Chassy, Cheryl Asa

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Bisdiamines have potential as a male contraceptive due to their ability to arrest spermatogenesis. The bisdiamine WIN 18,446, has proven safe and effective in grey wolves, domestic dogs, rats, and humans, but the unique drug metabolism of cats make extrapolation to felids inappropriate. This study used domestic cats to test the efficacy and safety of bisdiamines in felids. Five domestic cats were given 150 mg/kg WIN 18,446, mixed in food daily from Day 0 to Day 76, and were monitored until Day 152. Cats were observed daily and weighed weekly. Physical exam, hematology, clinical chemistry and urinalysis were conducted on Days 0, 7, 14, 28, 76, and 152 of the trial. Serum testosterone concentrations were measured on Days 0, 75, and 152. Unilateral orchectomies were performed on Days 76 and 152, and testes evaluated by histopathology. Spermatogenic arrest occurred in all cats during the treatment period, but normal spermatogenesis was restored by Day 152. Serum testosterone concentrations were lower on Day 76 (2.62±2.5 ng/ml; P<0.01) than Day 0 (7.3±1.0 ng/ml), but returned to pre-treatment concentrations in four of five cats by Day 152 (6.16±2.1 ng/ml; P>0.05). Clinical pathology parameters remained within reference ranges during the treatment period; however, urine calcium oxalate crystals were noted only during treatment in three cats. Bisdiamine (WIN 18,446) was a safe and effective contraceptive for male cats, but testosterone concentrations decreased during treatment.

Original languageEnglish (US)
Pages (from-to)81-92
Number of pages12
JournalTheriogenology
Volume62
Issue number1-2
DOIs
StatePublished - Jul 2004

Fingerprint

Male Contraceptive Agents
contraceptives
Cats
cats
Safety
testosterone
Testosterone
Felidae
spermatogenesis
Calcium Oxalate
Clinical Chemistry
calcium oxalate
Clinical Pathology
Urinalysis
urinalysis
Canis lupus
Hematology
Spermatogenesis
hematology
Serum

Keywords

  • Bisdiamine
  • Cat
  • Contraceptive
  • Male
  • Spermatogenic arrest
  • Testosterone

ASJC Scopus subject areas

  • Animal Science and Zoology
  • veterinary(all)

Cite this

Efficacy, safety and reversibility of bisdiamine as a male contraceptive in cats. / Munson, Linda; Chassy, Lisa M.; Asa, Cheryl.

In: Theriogenology, Vol. 62, No. 1-2, 07.2004, p. 81-92.

Research output: Contribution to journalArticle

Munson, Linda ; Chassy, Lisa M. ; Asa, Cheryl. / Efficacy, safety and reversibility of bisdiamine as a male contraceptive in cats. In: Theriogenology. 2004 ; Vol. 62, No. 1-2. pp. 81-92.
@article{9149c12aceb548caa2935db36dc039ca,
title = "Efficacy, safety and reversibility of bisdiamine as a male contraceptive in cats",
abstract = "Bisdiamines have potential as a male contraceptive due to their ability to arrest spermatogenesis. The bisdiamine WIN 18,446, has proven safe and effective in grey wolves, domestic dogs, rats, and humans, but the unique drug metabolism of cats make extrapolation to felids inappropriate. This study used domestic cats to test the efficacy and safety of bisdiamines in felids. Five domestic cats were given 150 mg/kg WIN 18,446, mixed in food daily from Day 0 to Day 76, and were monitored until Day 152. Cats were observed daily and weighed weekly. Physical exam, hematology, clinical chemistry and urinalysis were conducted on Days 0, 7, 14, 28, 76, and 152 of the trial. Serum testosterone concentrations were measured on Days 0, 75, and 152. Unilateral orchectomies were performed on Days 76 and 152, and testes evaluated by histopathology. Spermatogenic arrest occurred in all cats during the treatment period, but normal spermatogenesis was restored by Day 152. Serum testosterone concentrations were lower on Day 76 (2.62±2.5 ng/ml; P<0.01) than Day 0 (7.3±1.0 ng/ml), but returned to pre-treatment concentrations in four of five cats by Day 152 (6.16±2.1 ng/ml; P>0.05). Clinical pathology parameters remained within reference ranges during the treatment period; however, urine calcium oxalate crystals were noted only during treatment in three cats. Bisdiamine (WIN 18,446) was a safe and effective contraceptive for male cats, but testosterone concentrations decreased during treatment.",
keywords = "Bisdiamine, Cat, Contraceptive, Male, Spermatogenic arrest, Testosterone",
author = "Linda Munson and Chassy, {Lisa M.} and Cheryl Asa",
year = "2004",
month = "7",
doi = "10.1016/j.theriogenology.2003.07.026",
language = "English (US)",
volume = "62",
pages = "81--92",
journal = "Theriogenology",
issn = "0093-691X",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Efficacy, safety and reversibility of bisdiamine as a male contraceptive in cats

AU - Munson, Linda

AU - Chassy, Lisa M.

AU - Asa, Cheryl

PY - 2004/7

Y1 - 2004/7

N2 - Bisdiamines have potential as a male contraceptive due to their ability to arrest spermatogenesis. The bisdiamine WIN 18,446, has proven safe and effective in grey wolves, domestic dogs, rats, and humans, but the unique drug metabolism of cats make extrapolation to felids inappropriate. This study used domestic cats to test the efficacy and safety of bisdiamines in felids. Five domestic cats were given 150 mg/kg WIN 18,446, mixed in food daily from Day 0 to Day 76, and were monitored until Day 152. Cats were observed daily and weighed weekly. Physical exam, hematology, clinical chemistry and urinalysis were conducted on Days 0, 7, 14, 28, 76, and 152 of the trial. Serum testosterone concentrations were measured on Days 0, 75, and 152. Unilateral orchectomies were performed on Days 76 and 152, and testes evaluated by histopathology. Spermatogenic arrest occurred in all cats during the treatment period, but normal spermatogenesis was restored by Day 152. Serum testosterone concentrations were lower on Day 76 (2.62±2.5 ng/ml; P<0.01) than Day 0 (7.3±1.0 ng/ml), but returned to pre-treatment concentrations in four of five cats by Day 152 (6.16±2.1 ng/ml; P>0.05). Clinical pathology parameters remained within reference ranges during the treatment period; however, urine calcium oxalate crystals were noted only during treatment in three cats. Bisdiamine (WIN 18,446) was a safe and effective contraceptive for male cats, but testosterone concentrations decreased during treatment.

AB - Bisdiamines have potential as a male contraceptive due to their ability to arrest spermatogenesis. The bisdiamine WIN 18,446, has proven safe and effective in grey wolves, domestic dogs, rats, and humans, but the unique drug metabolism of cats make extrapolation to felids inappropriate. This study used domestic cats to test the efficacy and safety of bisdiamines in felids. Five domestic cats were given 150 mg/kg WIN 18,446, mixed in food daily from Day 0 to Day 76, and were monitored until Day 152. Cats were observed daily and weighed weekly. Physical exam, hematology, clinical chemistry and urinalysis were conducted on Days 0, 7, 14, 28, 76, and 152 of the trial. Serum testosterone concentrations were measured on Days 0, 75, and 152. Unilateral orchectomies were performed on Days 76 and 152, and testes evaluated by histopathology. Spermatogenic arrest occurred in all cats during the treatment period, but normal spermatogenesis was restored by Day 152. Serum testosterone concentrations were lower on Day 76 (2.62±2.5 ng/ml; P<0.01) than Day 0 (7.3±1.0 ng/ml), but returned to pre-treatment concentrations in four of five cats by Day 152 (6.16±2.1 ng/ml; P>0.05). Clinical pathology parameters remained within reference ranges during the treatment period; however, urine calcium oxalate crystals were noted only during treatment in three cats. Bisdiamine (WIN 18,446) was a safe and effective contraceptive for male cats, but testosterone concentrations decreased during treatment.

KW - Bisdiamine

KW - Cat

KW - Contraceptive

KW - Male

KW - Spermatogenic arrest

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=2642547598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642547598&partnerID=8YFLogxK

U2 - 10.1016/j.theriogenology.2003.07.026

DO - 10.1016/j.theriogenology.2003.07.026

M3 - Article

C2 - 15159103

AN - SCOPUS:2642547598

VL - 62

SP - 81

EP - 92

JO - Theriogenology

JF - Theriogenology

SN - 0093-691X

IS - 1-2

ER -